Skip to main content

Unable to load price data. Sorry.


OSI Pharmaceuticals, Inc. (NASDAQ:OSIP.DL)

CAPS Rating: No stars

A mid-cap biotechnology company committed to building a scientifically strong and financially successful top tier biopharmaceutical organization that discovers, develops and commercializes innovative molecular targeted therapies.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:OSIP.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

NetscribeBiotech (74.49)
Submitted May 28, 2007

OSI pharmaceutical is looking to position itself as a specialty player in the oncology market through its drug Tarceva, which has booked global sales worth $650 million in 2006 alone. The company’s partnership with Genetech and Roche to market… More

esebeus (< 20)
Submitted February 03, 2007

Once Tarceva becomes obsolete around 2009, this stock is junk. Bad mgmt. Poor upside.


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about OSIP.DL.

No one has written a Pitch for OSIP.DL stock yet. Tell us why you think OSIP.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in OSIP.DL.

No players have picked OSIP.DL yet. Tell us why you think OSIP.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OSIP.DL.